TABLE 2.
Clinical characteristics of patients with metastatic CRPC treated with beta-emitting PSMA-TRT
| Characteristics | Value (n=215) |
|---|---|
| Age (yrs), median (range) | 70.8 (44.6–93.4) |
| ECOG PS, n(%) | |
| 0 | 19 (8.8) |
| 1 | 177 (82.3) |
| 2 | 18 (8.4) |
| 3 | 1 (0.5) |
| Gleason sum, n(%) | |
| ≤6 | 35 (16.3) |
| 7 | 60 (27.9) |
| 8–10 | 117 (54.4) |
| PSA baseline (ng/ml), median (range) | 73.55 (0.49 – 2746) |
| Sites of metastases, n(%) | |
| Bone | 193 (89.8) |
| Lymph node | 117 (54.4) |
| Lung | 35 (16.3) |
| Liver | 19 (8.8) |
| Other | 7 (3.2) |
| CALGB prognostic group, n(%) | |
| High | 139 (64.6) |
| Intermediate | 67 (31.2) |
| Low | 9 (4.2) |
| Previous therapies, n(%) | |
| Taxanes | 129 (60.0) |
| Abiraterone/Enzalutamide | 65 (30.2) |
| Radium-223 | 15 (6.9) |
| Sipuleucel-T | 22 (10.2) |
| Beta-emitting PSMA-TRT types, n(%) | |
| 177Lu-J591 | 137 (63.7) |
| 177Lu-PSMA-617 | 44 (20.5) |
| 90Y-J591 | 28 (13.0) |
| 177Lu-J591 + 177Lu-PSMA-617 | 6 (2.8) |
| Dose level, n(%) | |
| Low | 111 (51.6) |
| Full | 104 (48.4) |
| PSMA imaging | |
| SPECT | 171 (79.5) |
| PET | 44 (20.5) |